Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 497 Cr.
- Current Price ₹ 319
- High / Low ₹ 392 / 178
- Stock P/E 58.7
- Book Value ₹ 67.8
- Dividend Yield 0.00 %
- ROCE 16.7 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 72.5 to 91.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 36 | 55 | 74 | 101 | 122 | 137 | |
| 33 | 50 | 65 | 86 | 105 | 122 | |
| Operating Profit | 3 | 5 | 9 | 15 | 17 | 15 |
| OPM % | 7% | 9% | 12% | 15% | 14% | 11% |
| 1 | 1 | 1 | 1 | 2 | 2 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 |
| Profit before tax | 1 | 4 | 7 | 12 | 15 | 12 |
| Tax % | 27% | 28% | 26% | 25% | 25% | 27% |
| 1 | 3 | 6 | 9 | 11 | 8 | |
| EPS in Rs | 5.10 | 13.60 | 27.50 | 8.97 | 7.97 | 5.44 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 23% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 53% |
| 3 Years: | 15% |
| TTM: | -24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 21% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 44 | 90 |
| 9 | 11 | 23 | 26 | 8 | 0 | |
| 7 | 13 | 14 | 13 | 12 | 60 | |
| Total Liabilities | 21 | 31 | 49 | 60 | 78 | 166 |
| 4 | 4 | 4 | 16 | 16 | 17 | |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 16 |
| 16 | 22 | 37 | 44 | 61 | 133 | |
| Total Assets | 21 | 31 | 49 | 60 | 78 | 166 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 2 | 7 | 9 | 7 | -15 | ||
| -1 | -5 | -7 | -3 | -3 | ||
| -1 | -1 | -2 | -3 | 23 | ||
| Net Cash Flow | 0 | 1 | 0 | 2 | 5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 75 | 70 | 64 | 55 | 71 | 92 |
| Inventory Days | 90 | 80 | 96 | 93 | 88 | 118 |
| Days Payable | 80 | 105 | 69 | 45 | 29 | 36 |
| Cash Conversion Cycle | 85 | 45 | 91 | 102 | 129 | 173 |
| Working Capital Days | 86 | 52 | 91 | 101 | 120 | 104 |
| ROCE % | 32% | 34% | 37% | 29% | 17% |
Documents
Announcements
-
Outcome of Board Meeting
28 May 2025 - Approved audited FY25 standalone and consolidated financial results; appointed internal auditor; no IPO fund deviation.
-
Board Meeting Intimation
22 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Board Meeting Intimation
22 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Board Meeting Intimation
10 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 23-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Price movement
25 April 2025 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
Annual reports
Concalls
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis